ovarian cancer	is a	gynecologic cancer
ovarian cancer	is a	malignant tumor of ovary
ovarian cancer	has histology	epithelial ovarian cancer
ovarian cancer	presents with	abdominal distension
ovarian cancer	presents with	pelvic mass
ovarian cancer	associated with	CA-125
ovarian cancer	associated with	BRCA1 mutation
ovarian cancer	associated with	BRCA2 mutation
ovarian cancer	associated with	homologous recombination deficiency
ovarian cancer	prognosis depends on	stage at diagnosis
ovarian cancer	prognosis depends on	residual disease after surgery
ovarian cancer	prognosis depends on	histology type
ovarian cancer	treated with	cytoreductive surgery
cytoreductive surgery	aims for	optimal debulking
ovarian cancer	treated with	platinum-based chemotherapy
carboplatin	is a	platinum agent
paclitaxel	is a	taxane
carboplatin	combined with	paclitaxel
intraperitoneal chemotherapy	used for	ovarian cancer
olaparib	is a	PARP inhibitor
niraparib	is a	PARP inhibitor
rucaparib	is a	PARP inhibitor
bevacizumab	is a	anti-angiogenic agent
bevacizumab	used in	ovarian cancer
neoadjuvant chemotherapy	used as	initial therapy for ovarian cancer
neoadjuvant chemotherapy	followed by	interval debulking surgery
interval debulking surgery	is performed after	neoadjuvant chemotherapy
ovarian cancer	is staged as	FIGO stage IV
FIGO stage	describes	ovarian cancer extent
ovarian cancer	histology type	high-grade serous carcinoma
high-grade serous carcinoma	is a	histology
ovarian cancer	metastasizes to	peritoneum
ovarian cancer	metastasizes to	omentum
ascites	is a complication of	ovarian cancer
ovarian cancer	associated with	ascites
CA-125	is a	tumor marker
CA-125 elevation	indicates	disease activity
HE4	is a	tumor marker
ovarian cancer	tested for	CA-125
ovarian cancer	tested for	HE4
germline BRCA mutation	increases risk for	ovarian cancer
Lynch syndrome	increases risk for	ovarian cancer
endometriosis	increases risk for	ovarian cancer
obesity	increases risk for	ovarian cancer
nulliparity	increases risk for	ovarian cancer
age	increases risk for	ovarian cancer
family history	increases risk for	ovarian cancer
ovarian cancer	can present as	abdominal symptoms
interval debulking surgery	used for	advanced ovarian cancer
optimal debulking	associated with	improved survival
residual disease	predicts	poorer survival
platinum-based chemotherapy	improves	progression-free survival
platinum-based chemotherapy	improves	overall survival
carboplatin	causes	thrombocytopenia
paclitaxel	causes	neuropathy
bevacizumab	associated with	hypertension
maintenance therapy	used for	ovarian cancer
olaparib	used for	BRCA-mutated ovarian cancer
niraparib	used for	ovarian cancer regardless of BRCA status
surveillance	used for	ovarian cancer recurrence
neutropenia	is an	adverse event of platinum-based chemotherapy
neurotoxicity	is an	adverse event of paclitaxel
thrombocytopenia	is an	adverse event of chemotherapy
ascites	worsens	quality of life
tumor burden	correlates with	prognosis
lymph node metastasis	indicates	advanced disease
imaging	informs	ovarian cancer staging
CT scan	used for	ovarian cancer staging
MRI	used for	ovarian cancer staging
pathology	confirms	histology type
germline testing	informs	treatment selection
somatic testing	informs	treatment selection
genetic testing	recommended for	ovarian cancer patients
cytoreductive surgery	improves	survival
recurrent ovarian cancer	classified as	platinum-sensitive
recurrent ovarian cancer	classified as	platinum-resistant
PARP inhibitors	used as	maintenance therapy
treatment response	assessed by	CA-125 level
treatment response	assessed by	imaging
tumor markers	used for	monitoring
ovarian cancer	increases risk of	thromboembolism
thromboembolism	leads to	hospitalization
tumor markers	indicate	prognosis
surgical debulking	reduces	tumor burden
cytoreduction	reduces	tumor burden
bevacizumab	approved for	ovarian cancer
bevacizumab	delays	progression
parp inhibitors	cause	anemia
anemia	leads to	transfusion
transfusion	required for	anemia
ovarian cancer	presents with	ascites
ascites	worsens	survival
surgical resection	improves	survival
chemotherapy	reduces	tumor size
tumor size	correlates with	survival
tumor cytoreduction	improves	survival
comorbidity	influences	treatment choice
age	affects	treatment tolerance
BRCA mutation status	informs	PARP inhibitor eligibility
incomplete debulking	increases	recurrence risk
